Abstract
Between June 2003 and January 2004, we studied the in vitro activity of prulifloxacin (PUFX) against clinical isolates causing otorhinolaryngological infection: coagulase negative Staphylococcus (CNS), Staphylococcus aureus, α-Streptococcus, Streptococcus pneumoniae, Corynebacterium spp., Branhamella catarrhalis, and Haemophilus influenzae.
1) MIC80 and MIC90 for CNS were 4.0μg/ml, and susceptibility distribution showed two peaks, at 0.125μg/ml and 4.0μg/ml.
2) MIC80 and MIC90 for S. aureus were 0.5μg/ml and 8.0μg/ml, and susceptibility distribution showed two peaks, at 0.25μg/ml and 0.5μg/ml.
3) MIC80 and MIC90 for α-Streptococcus were 4.0μg/ml, and susceptibility distribution showed one peak, at 2.0μg/ml.
4) MIC80 and MIC90 for S. pneumoniae were 2.0μg/ml, and susceptibility distribution showed two peaks, at 1.0μg/ml and 2.0μg/ml.
5) MIC80 and MIC90 for Corynebacterium spp. were 8.0μg/ml and 32.0μg/ml, and susceptibility distribution showed two peaks, at 0.5μg/ml and 32.0μg/ml.
6) MICK80 and MIC90 for B. catarrhalis were 0.125μg/ml, and susceptibility distribution showed one peak, at 0.125μg/ml.
7) MC80 and MIC90 for H. influenzae were 0.031μg/ml, and susceptibility distribution showed one peak, at 0.031μg/ml.
Compared to other new quinolone antimicrobial agents for Gram-positive bacteria-except gatifloxacin (GFLX), which showed good activity-PUFX showed activity almost equal to that of ciprofloxacin (CPFX) and levofloxacin (LVFX). For Gram-negative bacteria, PUFX showed activity almost equal to that of GFLX, CPFX, and LVFX. We concluded that we get good results with PUFX in patients with otorhinolaryngological infection caused by the above strains.
